



1712

RECEIVED
JAN 15 2002
TC 1700

PATENT

1642
IDS/#5
1/22/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	M. Suthanthiran, et al.	Examiner:	Unassigned
Serial No.:	09/780,953	Group Art Unit:	Unassigned
Confirmation No:	1712	Docket:	955-3P/CON
Filed:	February 9, 2001	Dated:	December 7, 2001
For:	Use of TGF- β Antagonists to Inhibit Tumor Cell Formation or Progression		

TECH CENTER 1600/2900

JAN 22 2002

RECEIVED

Assistant Commissioner for Patents
Washington, DC 20231

*I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:
Assistant Commissioner for Patents, Washington, D.C.*

20231 on December 7, 2001

Dated: 12/7/01

Carol M. Bryan

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicants submit herewith the following Supplemental Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98. This disclosure supplements the original Information Disclosure Statement filed on November 13, 2001.

UNITED STATES PATENTS

<u>PATENTEE</u>	<u>PATENT NO.</u>	<u>ISSUE DATE</u>
Bursuker, et al.	5,147,799	September 15, 1992
Keller, et al.	5,278,145	January 11, 1994
Carlino	5,426,098	June 20, 1995
Sporn, et al.	5,656,587	August 12, 1997

NON-PATENT PUBLICATIONS

1. B. Li, P. K. Sehajpal, A. Khanna, H. Vlassara, A. Cerami, K. H. Stenzel, and M. Suthanthiran, "Differential Regulation of Transforming Growth Factor β and Interleukin 2 Genes in Human T Cells: Demonstration by Usage of Novel Competitor DNA Constructs in the Quantitative Polymerase Chain Reaction," *J. Exp. Med.* (1991) 174: 1259-1262.
2. Ashwani Khanna, Baogui Li, Kurt H. Stenzel, and Manikkam Suthanthiran, "Regulation of New DNA Synthesis in Mammalian Cells by Cyclosporine," *Transplantation* (1994) 57: 577-582.
3. Bottinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM, "Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene," *Cancer Res.* (1997) 57: 5564-5570 (Abstract Only).

The above-referenced documents are listed on PTO Form 1449. We have enclosed the cited documents to facilitate reference to them. The Examiner is respectfully requested to consider these publications in their entirety, and to indicate that he or she has done so by initialing the enclosed form PTO 1449.

The Supplemental Information Disclosure Statement is submitted before the first Office Action, therefore, it is believed that no fee is due. However, if a fee is due, the Commissioner is hereby authorized to charge any fees associated with this communication to Deposit Account No. 08-2461. A duplicate copy of this paper is attached for that purpose.

Applicants are not aware of any other references to be identified at this time. If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicants' attorney at the telephone number set forth below.

Respectfully submitted,



Algis Anilionis, Ph.D.
Registration No.: 36,995
Attorney for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550

AA/nr
145841_1